Orion Biotechnology

Orion Biotechnology is a clinical stage company founded in 2011 and headquartered in Canada. The company's slogan, "Precision engineering GPCR-targeted therapeutics," reflects its mission to develop next-generation therapeutics for effectively targeting G Protein-Coupled Receptors (GPCRs). Orion has garnered significant attention with its proprietary technology platform that enables the precise targeting of previously undruggable complex GPCRs. The company's pipeline includes 3 next-generation therapeutics for cancer, with OB-002 as its lead candidate. Positioned as a first-in-class cancer immunotherapy, OB-002 boasts best-in-class potency. Orion’s innovative approach to therapeutics has drawn substantial investment, with its last funding round amounting to $11.50M in a Series A investment on 05 May 2021. Notably, the investment was made by a consortium of investors including Keiretsu Capital, Keiretsu Forum Northwest, Globivest, Sidedoor Ventures, SevenTrainVentures. With a focus on the biotechnology and healthcare industries, Orion Biotechnology is poised to make a significant impact in the field of precision medicine and targeted therapeutics.